These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 2313334

  • 1. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE.
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF.
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [Abstract] [Full Text] [Related]

  • 3. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 4. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J.
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [Abstract] [Full Text] [Related]

  • 5. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [Abstract] [Full Text] [Related]

  • 6. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF.
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [Abstract] [Full Text] [Related]

  • 7. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P.
    J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
    Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE.
    Biol Blood Marrow Transplant; 2001 Mar; 7(10):552-60. PubMed ID: 11760087
    [Abstract] [Full Text] [Related]

  • 9. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
    Vaughan WP, Kris E, Vose J, Bierman PJ, Gwilt P, Armitage JO.
    J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
    [Abstract] [Full Text] [Related]

  • 10. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP.
    J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
    [Abstract] [Full Text] [Related]

  • 11. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C.
    J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB.
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [Abstract] [Full Text] [Related]

  • 13. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG.
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [Abstract] [Full Text] [Related]

  • 14. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL, Miller KB.
    J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
    [Abstract] [Full Text] [Related]

  • 16. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
    Rosenfeld CS, Przepiorka D, Schwinghammer TL, Buck DS, Bloom EJ, Shadduck RK.
    Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183
    [Abstract] [Full Text] [Related]

  • 17. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
    Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG.
    Ann Oncol; 1991 Jan; 2 Suppl 1():47-50. PubMed ID: 2043498
    [Abstract] [Full Text] [Related]

  • 18. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D.
    J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
    [Abstract] [Full Text] [Related]

  • 19. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G.
    J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
    [Abstract] [Full Text] [Related]

  • 20. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
    Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ.
    Blood; 1995 Jul 15; 86(2):451-6. PubMed ID: 7541661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.